Community optometrists able to diagnose glaucoma accurately

Article

Community optometrists trained in glaucoma can provide satisfactory decisions regarding diagnosis and initiation of treatment.

Community optometrists trained in glaucoma can provide satisfactory decisions regarding diagnosis and initiation of treatment, according to a report published online ahead of print by the British Journal of Ophthalmology.

Augusto Azuara Blanco and colleagues from the Aberdeen Royal Infirmary and the University of Aberdeen, UK compared the diagnostic abilities of accredited glaucoma optometrists (AGO) with that of routine hospital eyecare against a reference standard of expert opinion, i.e. consultant ophthalmologists with a special interest in glaucoma.

A total of 100 subjects were examined. People suspected of having glaucoma underwent full assessment both in the newly established, optometry led glaucoma management scheme and in a consultant led hospital eye service.

Agreement between the AGO and consultant ophthalmologists was significant at 89%. Agreement regarding the need for treatment was also substantial (88%) whilst the agreement between trainee ophthalmologist and consultant ophthalmologist was moderate (83%).

It was concluded that community optometrists trained in glaucoma are able to offer satisfactory diagnoses and initiation of treatment.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.